Allogene Therapeutics Company Profile
Allogene Therapeutics Inc, founded in 2017 and headquartered in South San Francisco, is a public clinical-stage immuno-oncology company (stock symbol ALLO) specializing in genetically engineered allogeneic "off-the-shelf" T cell therapies targeting cancer and autoimmune diseases, with core programs in Large B-Cell Lymphoma, Autoimmune Disease, and Renal Cell Carcinoma, currently holding 109 granted and 122 pending patents, a market cap of $656 million as of June 2026, and reporting significant net losses and zero revenue in recent financials.
Overview
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC).
- Year Founded: 2017
- Status: Public
- Employees: 152
- Stock Symbol: ALLO
- Investments: 5
- Share Price: $1.90 (as of 12-Jun-2026)
- Market Cap: $656M (345M shares)
- Primary Industry: Drug Discovery
- Other Industries: Biotechnology
- Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080, United States
- Website: www.allogene.com
Stock Performance (as of 12-Jun-2026)
- Stock Price: $1.90
- Previous Close: $1.88
- 52 Week Range: $0.98 - $4.46
- Market Cap: $656M
- Shares: 345M
- Average Volume: 10.1M
- EPS: -$0.77
Financials Summary (as of 31-Mar-2026)
| In Thousands, USD | TTM 31-Mar-2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV | 427,861 | 132,820 | 240,173 | 164,765 |
| Revenue | 0 | 0 | 22 | 95 |
| EBITDA | (177,752) | (196,700) | (263,519) | (331,373) |
| Net Income | (173,760) | (190,886) | (257,590) | (327,265) |
| Total Assets | 395,958 | 415,905 | 548,710 | 642,837 |
| Total Debt | 72,633 | 83,253 | 90,756 | 95,121 |
Patents
- Total Documents (Applications and Grants): 286
- Total Patent Families: Not specified
- Granted: 109
- Pending: 122
- Expiring in next 12 months: Not specified
Recent Patent Activity
- WO-2026064719-A1: Cd19 anti-idiotypic antibodies (Pending, 22-Sep-2024)
- AU-2024369584-A1: Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof (Pending, 30-Oct-2023)
- WO-2025096594-A2: Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof (Pending, 30-Oct-2023)
- WO-2025096594-A3: Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof (Pending, 30-Oct-2023)
- AU-2024372734-A1: Engineered cells (Pending, 30-Oct-2023, Technology: A61K40/11)
Investments (5)
Allogene Therapeutics’s most recent deal was a Corporate investment with Antion Biosciences on 22-Jul-2023.
| Company Name | Deal Date | Deal Type | Industry |
|---|---|---|---|
| Antion Biosciences | 22-Jul-2023 | Corporate | Biotechnology |
| Antion Biosciences | 11-Jan-2022 | Corporate | Biotechnology |
| Notch Therapeutics | 10-Feb-2021 | Early Stage VC | Biotechnology |
| Allogene Overland Biopharm | 15-Dec-2020 | Joint Venture | Drug Discovery |
| Notch Therapeutics | 01-Nov-2019 | Seed Round | Biotechnology |
Exits (2)
Allogene Therapeutics’s most recent exit was on 10-Feb-2021 from Notch Therapeutics, with 9 buyers.
| Company Name | Exit Date | Status | Buyers |
|---|---|---|---|
| Notch Therapeutics | 10-Feb-2021 | Completed | 9 buyers |
| Notch Therapeutics | 01-Nov-2019 | Completed | 6 buyers |
ESG (Environmental, Social, Governance)
- Risk Rating (as of June 4, 2026): 30.33 (High Risk)
- Risk Scale:
- Negligible: 0-10
- Low: 10-20
- Medium: 20-30
- High: 30-40
- Severe: 40+
- Exposure: Refers to the extent to which a company is exposed to different material ESG issues
- Management: Related to actions taken to manage ESG issues
Competitors
Some of Allogene Therapeutics’s competitors include:
- Fate Therapeutics (San Diego, CA)
- Vor Biopharma (Boston, MA)
- Blueprint Medicines (Cambridge, MA)
- Erasca (San Diego, CA)
- Adaptimmune Therapeutics (Abingdon, United Kingdom)
FAQs
When was Allogene Therapeutics founded?
Allogene Therapeutics was founded in 2017.
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics is headquartered in South San Francisco, CA.
What is the size of Allogene Therapeutics?
Allogene Therapeutics has 152 total employees.
What industry is Allogene Therapeutics in?
Allogene Therapeutics’s primary industry is Drug Discovery.
Is Allogene Therapeutics a private or public company?
Allogene Therapeutics is a Public company.
What is Allogene Therapeutics’s stock symbol?
The ticker symbol for Allogene Therapeutics is ALLO.
What is the current stock price of Allogene Therapeutics?
As of 12-Jun-2026 the stock price of Allogene Therapeutics is $1.90.
What is the current market cap of Allogene Therapeutics?
The current market capitalization of Allogene Therapeutics is $656M.
Who are Allogene Therapeutics’s competitors?
Fate Therapeutics, Vor Biopharma, Blueprint Medicines, Erasca, and Adaptimmune Therapeutics are some of the 94 competitors of Allogene Therapeutics.
What is Allogene Therapeutics’s annual earnings per share (EPS)?
Allogene Therapeutics’s EPS for 12 months was -$0.77.